retatrutide triple agonist obesity Michael Weintraub, MD on X: "Retatrutide, a (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight What are the side effects
Pay in 4 interest-free payments of $6.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22


























